Drug intelligence / Profile preview

18F-IMA601

Development stage: Unknown
Lead developer: Asceneuron
Modality: Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

18F-IMA601 is a fluorine-18 labeled radiotracer developed for PET imaging to quantify enzyme occupancy and central nervous system (CNS) target engagement of *O-GlcNAcase* (OGA), an enzyme involved in protein O-GlcNAcylation. The tracer enables noninvasive assessment of CNS OGA inhibition, serving as a pharmacodynamic biomarker in studies of *OGA inhibitors* (such as ASN51). 18F-IMA601 is used in clinical research—specifically in phase 1 studies—to visualize and measure OGA enzyme occupancy in the brain of healthy human volunteers[6][7].

Targets

OGA (Protein O-GlcNAcase)

Beyond the preview

Go deeper on 18F-IMA601.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 18F-IMA601.

Explore the full profile